SCHEMBL427002

SCHEMBL427002

N#Cc1ccc(OCc2ccccc2)cc1F

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.74
IMPDH2 P12268 1/20 0.57
MAOA P21397 2/20 0.54
ALOX5 P09917 1/20 0.51
MRGPRX4 Q96LA9 3/20 0.49
AS3MT Q9HBK9 2/20 0.48
NSD2 O96028 1/20 0.48
TOP1 P11387 1/20 0.48
TRPV4 Q9HBA0 1/20 0.47
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9190952 0.88 MAOB (0.62) MAOBIMPDH2MAOALMNACYP1A2
SCHEMBL4753464 0.88 MAOB (0.74) MAOBIMPDH2MAOAALOX5MRGPRX4
SCHEMBL4435816 0.88 MAOB (0.57) MAOBMAOACYP1A2CYP2C19NR4A2
SCHEMBL13735988 0.87 MAOB (0.57) MAOBIMPDH2MAOAALOX5MRGPRX4
SCHEMBL4424283 0.87 MAOB (0.56) MAOBMAOAMRGPRX4NR4A2
SCHEMBL3648539 0.85 MAOB (1.00) MAOBIMPDH2MAOAALOX5MRGPRX4
SCHEMBL18639804 0.85 MAOB (0.55) MAOBMAOAMRGPRX4TRPV4CYP11B1
SCHEMBL20465388 0.85 MAOB (0.76) MAOBMAOATRPV4CYP11B1CYP11B2
SCHEMBL8135327 0.85 MAOB (0.54) MAOBIMPDH2MAOACYP11B1CYP11B2
SCHEMBL188561 0.85 MAOB (0.55) MAOBMAOACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368114-A1 INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2024-11-07 US disclosed
CN-110105346-B Optionally substituted quinoline compounds 卫材R&D管理有限公司 2023-03-10 CN disclosed
EP-3995495-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS Eisai R&D Management Co., Ltd. (JP) 2022-05-11 EP disclosed
EP-3995495-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS Eisai R&D Management Co., Ltd. (JP) 2022-05-11 EP disclosed
US-20210198220-A1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2021-07-01 US disclosed
US-11001563-B2 SSAO inhibitor SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2021-05-11 US disclosed
EP-3133075-B1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-12-30 EP disclosed
US-20200115352-A1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO., LTD. 2020-04-16 US disclosed
EP-3626717-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS Eisai R&D Management Co., Ltd. (JP) 2020-03-25 EP disclosed
US-RE47193-E1 Selectively substituted quinoline compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-01-08 US disclosed
WO-1999043763-A1 LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS THE SECRETARY OF STATE FOR DEFENCE (GB) 1999-09-02 WO disclosed
EP-0835254-B1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1999-09-01 EP disclosed
EP-0891358-A1 OXAZOLIDIN-2-ONE DERIVATIVES, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF SYNTHELABO (FR) 1999-01-20 EP disclosed
US-5843975-A Oxazolidinone derivatives, their preparation and therapeutical use SYNTHELABO (FR) 1998-12-01 US disclosed
EP-0835254-A1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1998-04-15 EP disclosed
WO-1997013768-A1 OXAZOLIDIN-2-ONE DERIVATIVES, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF SYNTHELABO (FR) 1997-04-17 WO disclosed
WO-1996038444-A1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1996-12-05 WO disclosed
US-5312564-A Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same CHISSO CORPORATION (JP) 1994-05-17 US disclosed
US-4780242-A BIPHENYL ESTERS CHISSO CORPORATION (JP) 1988-10-25 US disclosed
EP-0197677-A2 Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same Chisso Corporation (JP) 1986-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11001563-B2 SSAO inhibitor SSB, ASAH2, AOX1 MAOB 78/4885IMPDH2 551/4885MAOA 74/4885
US-20210198220-A1 SSAO INHIBITOR SSB, ASAH2, AOX1 MAOB 78/4885IMPDH2 551/4885MAOA 74/4885
US-20240368114-A1 INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1G3, CSNK1A1, CSNK1D MAOB 2502/4885IMPDH2 726/4885MAOA 2340/4885
US-20200115352-A1 SSAO INHIBITOR SSB, ASAH2, AOX1 MAOB 78/4885IMPDH2 551/4885MAOA 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.